Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Key Takeaways

• Signatera negativity predicts 100% one-year survival in ASCC
• ctDNA positivity precedes clinical recurrence in all ASCC relapses
• Signatera‑positive NOM patients face 4.6× higher regrowth risk
• Post‑operative Signatera negativity reduces relapse to 11.5%
• Early ctDNA monitoring guides organ‑preserving strategies in rectal cancer

Summary

Natera announced two peer‑reviewed studies demonstrating the clinical utility of its personalized ctDNA assay, Signatera, in anal squamous cell carcinoma and locally advanced rectal cancer. In the ASCC cohort of 84 patients, baseline negativity or clearance of ctDNA during chemoradiotherapy correlated with 100% one‑year overall and progression‑free survival, while persistent positivity predicted poorer outcomes and always preceded radiographic relapse. The LARC study of 220 patients showed that post‑neoadjuvant Signatera positivity identified patients at over four‑fold higher risk of tumor regrowth under non‑operative management, whereas postoperative negativity was linked to an 11.5% relapse rate. These data suggest Signatera can inform early treatment decisions and surveillance strategies across gastrointestinal malignancies.

Pulse Analysis

The rise of circulating tumor DNA (ctDNA) testing marks a pivotal shift in precision oncology, offering clinicians a minimally invasive window into tumor dynamics. Signatera, Natera’s tumor‑informed assay, tailors its detection panel to each patient’s unique genetic alterations, delivering highly specific signals of residual disease. As health systems prioritize value‑based care, such molecular tools promise earlier intervention points, potentially curbing costly downstream treatments and aligning with payer expectations for outcome‑driven reimbursement.

In anal squamous cell carcinoma, the recent Nature Communications study highlighted a stark dichotomy: patients who cleared ctDNA during chemoradiotherapy achieved perfect one‑year survival metrics, while those with lingering positivity faced markedly lower outcomes. Crucially, ctDNA positivity surfaced before any radiographic evidence of relapse, underscoring its role as a leading indicator. This early warning capability could reshape surveillance protocols, allowing oncologists to intensify imaging or consider adjuvant therapies precisely when molecular signals reappear, rather than adhering to fixed timelines.

The LARC investigation, published in Cancers, extended these insights to rectal cancer management. By stratifying patients after neoadjuvant therapy, Signatera identified a subset at over four times the risk of tumor regrowth when pursuing non‑operative management. Conversely, postoperative negativity correlated with an 11.5% relapse rate versus 88% among positives. These findings empower multidisciplinary teams to make data‑driven decisions about organ preservation versus surgical intervention, potentially reducing morbidity while maintaining oncologic safety. As more real‑world evidence accumulates, ctDNA‑guided pathways are poised to become standard components of gastrointestinal cancer care, driving both clinical and economic benefits.